WHAT IS CLAIMED IS:

1. A compound of Formula (**I-d1**):



Formula (**I-d1**)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{R^1}$ is -C(O)OH;

$\mathbf{Z^1}$ is CH or N;

$\mathbf{R^2}$ is $-CH_3$ or $-CF_3$;

a1b is 2, 3, or 4;

each $\mathbf{L^{A1b}}$ is $-CH_2-$;

$\mathbf{R^{Ya}}$ is C_{1-3} alkyl optionally substituted with 1-3 -F;

each $\mathbf{R^{Yb}}$ is independently selected from the group consisting of: -F, C_{1-3} alkoxy, and C_{1-3} alkyl optionally substituted with 1-3 -F; and

c1 is 0, 1, or 2.

2. The compound of claim 1, wherein **a1b** is 3.

3. The compound of claim 1, wherein **a1b** is 4.

4. The compound of any one of claims 1-3, wherein **c1** is 0.

5. The compound of any one of claims 1-4, wherein $\mathbf{R^{Ya}}$ is methyl.

6. The compound of any one of claims 1-5, wherein $\mathbf{Z^1}$ is N.

7. The compound of any one of claims 1-5, wherein $\mathbf{Z^1}$ is CH.

8. The compound of any one of claims 1-7, wherein $\mathbf{R^2}$ is $-CH_3$.

9. The compound of any one of claims 1-7, wherein $\mathbf{R^2}$ is $-CF_3$.

10. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1, wherein the compound is:


, or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, wherein the compound is:


, or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, wherein the compound is:


, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1, wherein the compound is:



,

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition, characterized by comprising a compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

25. Use of a compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 24, in the manufacture of a medicament for treating cancer.

26. The use of claim 25, wherein the medicament is configured for administration in combination with an additional therapy or therapeutic agent.

27. The use of claim 26, wherein the additional therapy or therapeutic agent is an ALK inhibitor, a BCL-2 inhibitor, a BCR-Abl inhibitor, a BRaf inhibitor, a CDK2 inhibitor, CDK 4/6 inhibitor, a CDK7 inhibitor, a CDK9 inhibitor, an EGFR inhibitor, an anti-EGFR antibody, an ERK inhibitor, a FGFR1 inhibitor, a FGFR2 inhibitor, a FGFR3 inhibitor, a FGFR4 inhibitor, a HER2 inhibitor, a JAK2 inhibitor, a KRas inhibitor, a MEK inhibitor, a MET inhibitor, a PARP inhibitor, an LSD1 inhibitor, a BET inhibitor, a telomerase inhibitor, a TORC1/2 inhibitor, L-asparaginase, chemotherapy, radiotherapy, or a combination thereof.

28. The use of any one of claims 25-27, wherein the cancer is breast cancer, bile duct cancer, colorectal cancer, gastrointestinal stromal tumor, pancreatic cancer, bladder cancer, kidney cancer, cervical cancer, ovarian cancer, uterine cancer, head and neck cancer, hematological cancer, lung cancer, skin cancer, or a combination thereof.

29. The use of claim 28, wherein the hematological cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), essential thrombocythemia, polycythemia vera, myelofibrosis, or a combination thereof.

30. A compound of any one of claims 1-23 for use in therapy.